Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
MRK | NYSE | USD | Real-time | |
0QAH | London | USD | Real-time | |
MRK | Mexico | MXN | Delayed | |
1MRKX | Milan | EUR | Real-time | |
MRK | Xetra | EUR | Delayed | |
MRK | TradeGate | EUR | Delayed | |
MRK | Frankfurt | EUR | Delayed | |
MRKm | Buenos Aires | ARS | Delayed | |
MRCK34 | B3 | BRL | Delayed | |
MRK | Vienna | EUR | Real-time | |
MRK | Ukraine | UAH | Delayed | |
MRK | Lima | USD | Delayed |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Name | Age | Since | Title |
---|---|---|---|
Patricia F. Russo | 70 | 1995 | Independent Director |
Thomas Henry Glocer | 63 | 2007 | Independent Lead Director |
Pamela J. Craig | 65 | 2015 | Independent Director |
Robert M. Davis | 55 | 2014 | CEO & Chairman |
Paul B. Rothman | 66 | 2015 | Independent Director |
Inge G. Thulin | 70 | 2018 | Independent Director |
Mary Ellen Coe | 56 | 2019 | Independent Director |
Kathy J. Warden | 52 | 2020 | Independent Director |
Risa J. Lavizzo-Mourey | 69 | 2020 | Independent Director |
Douglas M. Baker | 65 | 2022 | Independent Director |
Christine E. Seidman | 71 | 2020 | Independent Director |
Stephen L. Mayo | 62 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review